New drug cocktail aims to outsmart resistant leukemia

NCT ID NCT06232655

Ongoing Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs, cladribine and venetoclax, in 20 adults with a specific form of acute myeloid leukemia (monocytic AML) that has stopped responding to or returned after standard treatment. The goal is to see if this new combo can shrink or eliminate the cancer. Researchers will also monitor side effects and how long any benefits last.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cladribine and venetoclax (chemotherapy and targeted therapy drugs)
What this could lead to: If successful, this could offer a new treatment option for people with a hard-to-treat form of acute myeloid leukemia that has stopped responding to standard therapy.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to all patients. The drugs can cause serious side effects, and there is no guarantee the combination will work better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute monocytic leukemia acute myeloid leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Universtiy of Colorado Hospital

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.